Arizona State Retirement System Grows Stock Position in Repligen Co. (NASDAQ:RGEN)

Arizona State Retirement System raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 15,410 shares of the biotechnology company’s stock after buying an additional 126 shares during the period. Arizona State Retirement System’s holdings in Repligen were worth $2,218,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of RGEN. Champlain Investment Partners LLC raised its stake in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after buying an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. raised its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after buying an additional 102,100 shares during the last quarter. Finally, Fred Alger Management LLC raised its stake in shares of Repligen by 29.5% during the 3rd quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock valued at $59,313,000 after buying an additional 90,831 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent research reports. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Trading Down 12.0 %

RGEN stock opened at $136.99 on Tuesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The stock has a market cap of $7.68 billion, a price-to-earnings ratio of -268.61, a PEG ratio of 4.54 and a beta of 0.95. The business’s 50-day moving average is $157.09 and its 200 day moving average is $148.51.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.